naproxen has been researched along with valdecoxib in 27 studies
| Studies (naproxen) | Trials (naproxen) | Recent Studies (post-2010) (naproxen) | Studies (valdecoxib) | Trials (valdecoxib) | Recent Studies (post-2010) (valdecoxib) |
|---|---|---|---|---|---|
| 4,551 | 1,057 | 1,429 | 375 | 71 | 86 |
| Protein | Taxonomy | naproxen (IC50) | valdecoxib (IC50) |
|---|---|---|---|
| Cytochrome c oxidase subunit 2 | Homo sapiens (human) | 1.1 | |
| Carbonic anhydrase 1 | Homo sapiens (human) | 0.1915 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 1.0086 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 2.927 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 2.927 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.0631 | |
| Carbonic anhydrase 9 | Homo sapiens (human) | 0.027 | |
| Carbonic anhydrase 4 | Bos taurus (cattle) | 0.2658 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 24 (88.89) | 29.6817 |
| 2010's | 3 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bevirt, T; Makarowski, W; Recker, DP; Zhao, WW | 1 |
| Kent, JD; Leese, PT; Recker, DP; Talwalker, S | 1 |
| Bevirt, T; Eisen, G; Kivitz, A; Recker, DP; Zhao, WW | 1 |
| Shaughnessy, AF | 1 |
| Daniels, SE; Recker, DP; Snabes, MC; Talwalker, S; Torri, S; Verburg, KM | 1 |
| Bensen, W; Espinoza, L; Paperiello, B; Recker, DP; Riley, W; Weaver, A; Zhao, WW | 1 |
| Goldstein, JL; Kent, JD; Kivitz, AJ; Palmer, RC; Recker, DP; Verburg, KM | 1 |
| Burian, M; Geisslinger, G | 1 |
| Fitzgerald, GA | 1 |
| Dahlborg, R; Day, CA; Jacob, RF; Mason, RP; Walter, MF; Weng, Y | 1 |
| Daniels, SE; Desjardins, PJ; Torri, S | 1 |
| Goldstein, JL; Mayne, TJ; Rabeneck, L; Rublee, DA; Vu, A | 1 |
| Brown, MT; Kivitz, AJ; Verburg, KM; Williams, GW | 1 |
| Aisenberg, J; Berger, MF; Goldstein, JL; Lanza, F; Pan, S; Sands, GH; Schwartz, H | 1 |
| Kumar, A; Naidu, PS; Padi, SV; Seghal, N | 1 |
| Deray, G; Montalescot, G; Sibilia, J | 1 |
| Ashcroft, DM; Chen, LC | 1 |
| Kumar, A; Kumar, P; Naidu, PS; Padi, SS | 1 |
| Berger, M; Fiechtner, J; Gibofsky, A; Pan, S; Rodrigues, J | 1 |
| Blum, D; Cunnington, M; Funk, MJ; Mander, A; Qizilbash, N; Webb, D; Weil, J | 1 |
| Kumar, A; Kumar, P; Kumari, B | 1 |
4 review(s) available for naproxen and valdecoxib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Clinical pharmacology of the selective COX-2 inhibitors].
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Clinical Trials, Phase III as Topic; Cyclooxygenase Inhibitors; Diclofenac; Humans; Isoxazoles; Lactones; Naproxen; Osteoarthritis; Pain; Pain, Postoperative; Placebos; Pyrazoles; Sulfonamides; Sulfones | 2003 |
[What do we know about the cardiovascular toxicity of the NSAIDs?].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Follow-Up Studies; Humans; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Naproxen; Pyrazoles; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors | 2006 |
Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib; Humans; Isoxazoles; Lactones; Models, Statistical; Myocardial Infarction; Naproxen; Odds Ratio; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk; Risk Factors; Sulfonamides; Sulfones | 2007 |
11 trial(s) available for naproxen and valdecoxib
| Article | Year |
|---|---|
Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Chi-Square Distribution; Constipation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Double-Blind Method; Drug Administration Schedule; Dyspepsia; Humans; Isoenzymes; Isoxazoles; Membrane Proteins; Middle Aged; Naproxen; Osteoarthritis, Hip; Prostaglandin-Endoperoxide Synthases; Sulfonamides | 2002 |
Valdecoxib does not impair platelet function.
Topics: Adolescent; Adult; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Bleeding Time; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Female; Humans; Isoxazoles; Male; Middle Aged; Naproxen; Platelet Aggregation; Statistics, Nonparametric; Sulfonamides; Thromboxane B2 | 2002 |
Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Digestive System; Double-Blind Method; Female; Humans; Isoxazoles; Male; Middle Aged; Naproxen; Osteoarthritis; Pain Measurement; Sulfonamides; Treatment Outcome | 2002 |
Valdecoxib, a cyclooxygenase-2-specific inhibitor, is effective in treating primary dysmenorrhea.
Topics: Administration, Oral; Adolescent; Adult; Cross-Over Studies; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Dysmenorrhea; Female; Humans; Isoxazoles; Naproxen; Pain Measurement; Probability; Reference Values; Sulfonamides; Treatment Outcome | 2002 |
Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen.
Topics: Administration, Oral; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Female; Health Status; Humans; Isoxazoles; Joints; Male; Middle Aged; Naproxen; Pain Measurement; Self-Examination; Severity of Illness Index; Sulfonamides; Treatment Outcome | 2002 |
A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Gastrointestinal Diseases; Humans; Intestinal Mucosa; Isoxazoles; Naproxen; Osteoarthritis; Pain; Risk Factors; Sulfonamides | 2003 |
Valdecoxib for treatment of primary dysmenorrhea. A randomized, double-blind comparison with placebo and naproxen.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cross-Over Studies; Cyclooxygenase Inhibitors; Double-Blind Method; Dysmenorrhea; Female; Humans; Isoxazoles; Naproxen; Sulfonamides; Treatment Outcome | 2005 |
Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Dyspepsia; Female; Humans; Ibuprofen; Isoxazoles; Male; Middle Aged; Naproxen; Osteoarthritis; Pain Measurement; Patient Satisfaction; Placebos; Quality of Life; Sulfonamides; Treatment Outcome; Upper Gastrointestinal Tract | 2005 |
A comparison of valdecoxib and naproxen in the treatment of rheumatoid arthritis symptoms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Isoxazoles; Male; Middle Aged; Naproxen; Sulfonamides; Treatment Outcome | 2006 |
A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Humans; Isoxazoles; Male; Middle Aged; Naproxen; Stomach Ulcer; Sulfonamides | 2006 |
Efficacy and tolerability of valdecoxib in treating the signs and symptoms of severe rheumatoid arthritis: a 12-week, multicenter, randomized, double-blind, placebo-controlled study.
Topics: Activities of Daily Living; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Double-Blind Method; Female; Humans; Isoxazoles; Male; Middle Aged; Naproxen; Pain Measurement; Patient Satisfaction; Placebos; Severity of Illness Index; Sulfonamides; Time Factors; Treatment Outcome | 2007 |
12 other study(ies) available for naproxen and valdecoxib
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Right ballpark, wrong base: assessing safety of NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Isoxazoles; Lactones; Naproxen; Osteoarthritis; Peptic Ulcer; Sulfonamides; Sulfones | 2002 |
[Adverse effects of NSAID are insidious. No pain--despite life threatening gastric hemorrhage].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Humans; Isoxazoles; Naproxen; Peptic Ulcer Hemorrhage; Risk Factors; Stomach Ulcer; Sulfonamides | 2002 |
[Progress in therapy of rheumatism. New coxib works especially fast].
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Humans; Isoxazoles; Naproxen; Osteoarthritis, Knee; Sulfonamides; Treatment Outcome | 2003 |
[Pain therapy in rheumatism. After 65 years of age coxibs are the best choice].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Cyclooxygenase Inhibitors; Diclofenac; Gastrointestinal Hemorrhage; Humans; Isoxazoles; Naproxen; Prognosis; Rheumatic Diseases; Sulfonamides | 2003 |
Coxibs and cardiovascular disease.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; Epoprostenol; Gastrointestinal Diseases; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Naproxen; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk; Sulfonamides; Sulfones; Thromboxane A2; United States; United States Food and Drug Administration | 2004 |
Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs.
Topics: Animals; Antioxidants; Celecoxib; Cholesterol, LDL; Chromans; Cyclooxygenase Inhibitors; Diclofenac; Humans; Ibuprofen; Isoprostanes; Isoxazoles; Lactones; Meloxicam; Naproxen; Oxidation-Reduction; Pyrazoles; Sulfonamides; Sulfones; Thiazines; Thiazoles | 2004 |
Lessons to learn from the COX-2 saga. Yes, FDA reforms are needed. And marketing distorts how medications are used. But one moral to the story is that all drugs have risks.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug-Related Side Effects and Adverse Reactions; Humans; Isoxazoles; Lactones; Marketing of Health Services; Naproxen; Pyrazoles; Risk Assessment; Sulfonamides; Sulfones; United States; United States Food and Drug Administration | 2005 |
Differential effects of cyclooxygenase inhibitors on intracerebroventricular colchicine-induced dysfunction and oxidative stress in rats.
Topics: Acetylcholinesterase; Animals; Behavior, Animal; Brain; Cognition Disorders; Colchicine; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Glutathione; Injections, Intraventricular; Isoxazoles; Lipid Peroxidation; Male; Maze Learning; Memory; Naproxen; Nitrites; Oxidative Stress; Rats; Rats, Wistar; Space Perception; Spatial Behavior; Sulfonamides; Time Factors | 2006 |
Cyclooxygenase inhibition attenuates 3-nitropropionic acid-induced neurotoxicity in rats: possible antioxidant mechanisms.
Topics: Animals; Behavior, Animal; Brain; Cyclooxygenase Inhibitors; Glutathione; Isoxazoles; Lipid Peroxidation; Male; Malondialdehyde; Maze Learning; Memory; Motor Activity; Naproxen; Neuroprotective Agents; Neurotoxicity Syndromes; Nitrites; Nitro Compounds; Oxidative Stress; Propionates; Rats; Rats, Wistar; Succinate Dehydrogenase; Sulfonamides | 2007 |
Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Databases, Factual; Female; Follow-Up Studies; Humans; Isoxazoles; Lactones; Male; Middle Aged; Myocardial Infarction; Naproxen; Osteoarthritis; Proportional Hazards Models; Pyrazoles; Retrospective Studies; Risk Factors; Stroke; Sulfonamides; Sulfones; United States | 2008 |
Protective effects of selective and non-selective cyclooxygenase inhibitors in an animal model of chronic stress.
Topics: Animals; Anxiety; Catalase; Chronic Disease; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Models, Animal; Glutathione; Isoxazoles; Lactones; Lipid Peroxidation; Male; Meloxicam; Memory; Mice; Motor Activity; Naproxen; Nitrites; Random Allocation; Stress, Psychological; Sulfonamides; Sulfones; Thiazines; Thiazoles | 2010 |